Clinical Trial Update: Phase 3 Study for Efficacy and Safety Outcomes Data in Japanese Patients With Severe Hemophilia A [Phase 3]

View source ↗

Summary

BioMarin's Phase 3 trial evaluating efficacy and safety outcomes of valoctocogene roxaparvovec in Japanese patients with severe Hemophilia A has an update on it…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• valoctocogene roxaparvovec (Roctavian) (valoctocogene roxaparvovec)

Snippet

Sponsor: BioMarin Pharmaceutical | Conditions: Hemophilia A | Phase 3 | Status: ACTIVE_NOT_RECRUITING